| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.5 | 0.3 |
| Gross profit | 0.6 | 0.1 |
| Net income | -2.4 | -2.6 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +784.9% |
|---|---|
| Gross margin | 23.8% |
10-Q filed with the SEC, NASDAQ: ELAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pmgc Holdings Inc.: key numbers
- Share price
- $1.66Close, Nov 16
- Market cap
- $1.94M
- Shares outstanding
- 1.17MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pmgc Holdings Inc.
All →Pmgc Holdings Clinical Trial Data
PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.
Pmgc Holdings Equity Investment of $1.84M in Nuclea Energy Canada Inc.
PMGC Holdings Inc. entered into a subscription agreement to invest $1.845 million in secured debentures of Nuclea Energy Canada Inc. The investment is part of a larger $9 million offering intended to fund Nuclea Canada's acquisition of assets from Moltex Energy Limited. The debentures are non-interest bearing, non-convertible, and mature in three months or upon certain corporate events.
- Value
- $1.84M
- Counterparty
- Nuclea Energy Canada Inc.
- Term
- 3 months
Pmgc Holdings Investor Presentation
PMGC Holdings Inc. (doing business as NorthStrive Holdings Inc.) filed a formal investor presentation slide deck and a specific deck related to its Maritime Defense Technology. The materials are intended for use in upcoming presentations to investors and analysts regarding the company's strategy and operations.
Pmgc Holdings Other 8-K Filing
PMGC Holdings and its subsidiary NorthStrive Biosciences entered into a binding payment agreement with Longevity Health Holdings to secure royalty payments from the 2025 sale of the Elevai Skincare business. The agreement converts a 5% net sales royalty into scheduled monthly cash payments through August 2031, including interest and mandatory prepayments tied to future capital events. This restructuring provides PMGC with visible, non-dilutive cash flow while allowing it to focus on its core manufacturing and defense technology segments.
- Counterparty
- Longevity Health Holdings, Inc.
- Term
- through Aug 2031